Sepsis leadership T2 Biosystems has FDA-cleared rapid sepsis diagnostics and exclusive U.S. distribution partnerships, presenting an opportunity to expand hospital and IDN adoption through Cardinal Health and Vizient channels.

Lyme and expansion Strong near-term growth potential with T2Lyme Panel and planned Lyme panel as a laboratory-developed test, indicating upsell opportunities to infectious disease and microbiology laboratories seeking faster Lyme disease and co-infection workflows.

Strategic partnerships Existing supplier and distribution agreements with Cardinal Health in the U.S. and Canada create a scalable go-to-market path; explore additional distributors and regional partnerships to broaden market reach and volume.

Healthcare cost focus Platform aims to reduce mortality and healthcare costs through targeted early treatment; align sales narratives with hospital clinicians and value-based purchasing teams emphasizing total cost of care and readmission reductions.

Financial runway Mid-stage revenue in the tens of millions with substantial funding supports expansion; target multi-hospital systems and accountable care organizations leveraging Vizient and IDN collaborations to secure larger contracts.